Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 201
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines for marketing authorisation at its February 2016 meeting.
The CHMP recommended granting marketing authorisations for two medicines for the prevention and treatment of bleeding in patients with haemophilia B, Alprolix (eftrenonacog alfa) and Idelvion (albutrepenonacog alfa). Both these medicines have an orphan designation.
Click on this link for more information.
